Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

---------------------------------

Loss before taxes 3,324,241 4,113,231 84,961,498

Future income tax recovery - - (1,115,000)

-------------------------------------------------------------------------

Net loss and comprehensive loss

for the period 3,324,241 4,113,231 83,846,498

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and diluted loss per share (0.08) (0.11)

-----------------------------------------------------------

-----------------------------------------------------------

Weighted average number of shares

(basic and diluted) 41,180,748 38,231,859

-----------------------------------------------------------

-----------------------------------------------------------

See accompanying notes

Oncolytics Biotech Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

Cumulative

from

Three Month Three Month inception

Period Period on April 2,

Ending Ending 1998 to

March 31, March 31, March 31,

2008 2007 2008

$ $ $

------------------------------------------------------------------------

OPERATING ACTIVITIES

Net loss for the period (3,324,241) (4,113,231) (83,846,498)

De
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, oral ... gallstones, today announced financial results for the period ended ... Summary: , Reported cash and cash equivalents totaling ... at December 31, 2013.  , Reported a net ...
(Date:7/24/2014)... -- A novel combination of microscopy and data processing ... Ridge National Laboratory an unprecedented look at the surface ... electrochemical properties. , The research team led by ... of a perovskite manganite, a complex material that exhibits ... understand surface behavior could benefit researchers who are interested ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6ORNL study reveals new characteristics of complex oxide surfaces 2
... ARBOR, Mich., Oct. 24 Gene Codes ... immediate,availability of the next version of Sequencher, ... analysis program. Researchers in academic labs ... which contains the essential genetic instructions key ...
... (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will ... the Financial,Services Exchange (FSX) Investment Conference at the ... October 25, 2007. Immunosyn has obtained exclusive ... its largest shareholder, Argyll,Biotechnologies, LLC. Research suggests that ...
... Environment Where Scientists Thrive and Science is ... ... year, Abbott (NYSE: ABT ) has been named among the top ... Science is at the center of Abbott,s broad base of businesses. To,enhance ...
Cached Biology Technology:Gene Codes Corporation Announces Version 4.8 of Sequencher Software for DNA Sequence Assembly & Analysis 2Immunosyn Corporation to Present at FSX 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 3
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... biomedical engineering at the University of Houston, has ... artificial organ development., "Introduction to Tissue Engineering: Applications ... into the field of artificial organ development. Metin ... at UH, served as a series editor on ... other published books on the subject of growing ...
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... Omnicell, Inc . (NASDAQ: OMCL ), a ... analytics software for healthcare facilities, today announced that ... supply and medication management solutions with the new fourth ... decade as an Omnicell pharmacy and supply automation customer, ...
... The cerebellum is far more intensively involved in helping ... effectively in spatial environments our brain, and particularly our ... cerebellum contributes to the creation of this map through ... ability is inactivated, the brain is no longer able ...
... available in Chinese on EurekAlert! Chinese . ... have published new research that improves the survival and effectiveness ... Chang Chan, from the Chinese University of Hong Kong, is ... has led to a variety of breakthroughs as stem cell ...
Cached Biology News:Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 2Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 3Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 4The cerebellum as navigation assistant 2Reprogramming stem cells to a more basic form results in more effective transplant, study shows 2
... Reagent A - Fixation medium Reagent ... are intended for fixing cells in suspension ... cells with Reagent B. This procedure gives ... the morphological scatter characteristics of the cells ...
... Intended Use: Vision Mount is formulated for covering ... alcohol soluble OR alcohol insoluble end products. , ... ... with chromogens such as Fast-Red or AEC that require an ...
... Solution, High pH This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: